mRNA Acceleration with Translational Pharmaceutics® platform and CPI expertise

Recently announced partnership to accelerate the development of RNA-based therapies.
Read Announcement For program enquiries: Contact Us
Thierry Van Nieuwenhove, CEO at Quotient Sciences:
"The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months."
Further details

Interested to work with us?

The Quotient Sciences and CPI joint venture extends the application of Translational Pharmaceutics into mRNA-based therapeutics. If you are interested to learn more about how this can apply to your next drug program, contact us today for a preliminary discussion.

Contact Us
Learn more about Quotient Sciences' services

See how we can help you with your next drug program.

Clinical Pharmacology
Integrated first-in-human and clinical pharmacology programs that help you make critical decisions earlier.
Discover More
Drug Product Development & Manufacturing
Tailored services, from formulation development to clinical trial manufacturing and commercial production.
Discover More
Translational Pharmaceutics® Integrated Drug Development
Our unique approach to drug development accelerates the entire process by integrating clinical activities and real-time cGMP manufacturing.
Discover More
Case Studies
Discover how we've helped pharma and biotech organizations successfully meet their milestones.
See Examples
Get in touch
Humanity can't afford to wait, so neither can we.
Let's talk